Science Current Events | Science News | Brightsurf.com
 

Rejected Alzheimer's drug shows new potential

July 31, 2012

Study suggests that latrepirdine, which previously failed in clinical trials, may be successful if tested on patients with earlier stages of the disease

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of action behind latrepirdine in the current study, which is supported by the Cure Alzheimer's Fund.

Dr. Gandy's team randomly administered either latrepirdine or placebo to mice engineered to present the early stages of Alzheimer's disease and found that the drug halted both behavioral decline and progression of neuropathology. In evaluating how latrepirdine improved memory, John Steele, PhD, a neuroscience graduate student working with Dr. Gandy, and Lenard Lachenmayer, MD, a postdoctoral fellow working under the supervision of Zhenyu Yue, PhD, Associate Professor of Neurology at Mount Sinai, found that the drug enhanced autophagy, the so-called "self-eating" process of cells that protects the brain from neurodegeneration.

"When we learned that latrepirdine failed in patients in the United States in 2010, scientists around the world were disappointed and perplexed," Dr. Gandy said. "We wanted to find out why the drug did so well in Russia but then showed no effect in the global studies. The findings from our animal model studies indicated that this drug should not be discarded, and that, if its mechanism of action can be optimized, it still has potential."

Dr. Sano points out that not only did latrepirdene have significant and sustained effect in the Russian study but it also showed a mild effect in one study of patients with Huntington's disease.

"Since cognitive benefit is what really matters to patients and families, it is critical that we explore every mechanism by which it might occur," Dr. Sano said.

"While this is just the beginning, our research shows that this previously cast-off drug still has strong therapeutic promise," Dr. Gandy said. "Autophagy drugs are believed to hold great promise for a range of neurodegenerative diseases, and these data raise the question of whether further basic science work on latrepirdine might lead to optimization of the drug so that a more potent drug could be developed, and subsequently tested in human clinical trials.

"This is especially true since we know that latrepirdine is an extremely safe drug and in view of the recent failure of the first key trial of the drug bapineuzumab," Dr. Gandy added. "Also, as may be the case with all amyloid-lowering drugs, initiating latrepirdine trials before amyloid deposition begins may be the key. Now, with the new brain amyloid scans that began at Mount Sinai in June, we can easily establish who those patients are."

Looking ahead, Drs. Gandy, Yue, and their collaborators are planning to test latrepirdine in mouse models of other protein buildup diseases such as Parkinson's disease, Lewy body dementia, and chronic traumatic encephalopathy, the Alzheimer's-like condition athletes endure from boxing, football and hockey. Dr. Sano notes that so few agents show any improvement in cognition that it is critical that to exhaust every potential lead.

Mount Sinai has a long-standing legacy of critical breakthroughs in team research in Alzheimer's disease. Dr. Gandy is an internationally-renowned expert in understanding the amyloid plaques characteristic of Alzheimer's disease, and he led a team of researchers to the discovery of the first drugs that reduced amyloid buildup. Dr. Sano is a world leader in designing clinical trials to find treatments and preventions for cognitive loss and Alzheimer's disease. Together, their labs and the Mount Sinai Alzheimer's Disease Research Center and Center for Cognitive Health are focused on a strategic approach to translating clinical challenges into bench investigations and back.

The Mount Sinai Hospital / Mount Sinai School of Medicine


Related Alzheimer's Disease Current Events and Alzheimer's Disease News Articles


Scientists ID genes connected to wellbeing, depression and neuroticism
An international group of more than 190 scientists who analyzed the genomes of 298,420 individuals have found genetic variants that may influence our sense of wellbeing, depression and neuroticism.

First diagnosed case of Alzheimer's disease in HIV-positive individual reported
Georgetown University researchers are reporting the first case of Alzheimer's disease diagnosed in an HIV-positive individual.

Researchers visualize brain's serotonin pump, provide blueprint for new, more effective SSRIs
Researchers at Oregon Health & Science University's Vollum Institute have uncovered remarkably detailed 3-D views of one of the most important transporters in the brain - the serotonin transporter.

Vascular brain injury is evident in people in their 40s
A large, multi-center study led by the UC Davis School of Medicine for the first time has shown that people as young as their 40s have stiffening of the arteries that is associated with subtle structural damage to the brain that is implicated in cognitive decline and Alzheimer's disease later in life.

Can gene therapy provide a breakthrough in Alzheimer's disease?
Therapeutic gene transfer to specific brain regions in animal models of Alzheimer's disease has uncovered multiple potential treatment approaches that deserve to be considered as candidates for clinical applications, according to the article "Gene Therapy Strategies for Alzheimer's Disease: An Overview"), published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Body's immune system may play larger role in Alzheimer's disease than thought
Immune cells that normally help us fight off bacterial and viral infections may play a far greater role in Alzheimer's disease than originally thought, according to University of California, Irvine neurobiologists with the Sue & Bill Gross Stem Cell Research Center and the Institute for Memory Impairments and Neurological Disorders.

Penn research: An FDA-approved Alzheimer's drug could help smokers quit
Despite several safe drug therapies available to help smokers quit, three-quarters report relapsing within six months of a quit attempt.

How a waste product of exercise protects neurons from trauma damage
Researchers led by EPFL have found how lactate, a waste product of glucose metabolism can protect neurons from damage following acute trauma such as stroke or spinal cord injury.

Antibody provide a more exact Alzheimer's diagnosis radioactive tracers
For the first time, researchers have succeeded in passing an antibody through the blood-brain barrier to act as a tracer for PET imaging of the brain.

Best to sleep on it: Brain activity patterns during sleep consolidate memory
Why does sleeping on it help? This is the question tackled by new research at the University of Bristol, which reveals how brain activity during sleep sorts through the huge number of experiences we encounter every day, filing only the important information in memory.
More Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

Outsmarting Alzheimer's: What You Can Do To Reduce Your Risk

Outsmarting Alzheimer's: What You Can Do To Reduce Your Risk
by Kenneth S. Kosik (Author)


An easy-to-follow, research-based guide to the simple, low-cost choices that give the reader the power to reduce the risk of developing Alzheimer's disease and dementia; slow the progression of the disease; and mitigate symptoms and improve well-being.

Did you know that getting on the treadmill can help keep your brain sharp? Or that repeatedly staying up to catch the late show could increase the likelihood of being struck down by dementia? The dozens of choices you make over the course of any average day—ordering the curry versus the burger with fries, taking the stairs versus the elevator—all add up. Together with your family history, they establish your chances of getting Alzheimer’s years from now. No drugs or procedures can cure or even effectively treat Alzheimer’s...

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition
by Dr. Richard S Isaacson MD (Author)


Harvard-trained Neurologist Dr. Richard Isaacson answers the most common patient and caregiver questions on the treatment and prevention of Alzheimer's disease (AD). He shares his cutting edge, comprehensive approach in the fight against AD, the greatest public health crisis today. This groundbreaking book has been written especially for patients, caregivers, family members, and allied healthcare professionals. Dr. Isaacson writes in easy to understand terms and easy to read (larger-type) print to help educate and inform those confronting AD. He outlines his comprehensive and scientifically-based approach that includes a comprehenisve 9-week diet and nutrition plan, with examples of what to eat, what not to eat, and a food terminology guide to help read and understand nutrition labels. ...

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones
by Mary T Newport (Author)


In this second edition Dr. Newport, a neonatal practitioner, continues the story of Steve's progress and provides the most recent research on such topics as possible causes of Alzheimer's due to the herpes simplex virus and nitrosamine substances and how infection, inflammation and genetic makeup may affect an individual's response to fatty acid therapy.

The Alzheimer's Prevention & Treatment Diet

The Alzheimer's Prevention & Treatment Diet
by Richard S. Isaacson MD (Author), Christopher N. Ochner PhD (Author)


Alzheimer s disease (AD) is a type of dementia that can be very hard for both the patient and the caregiver. Currently, five million Americans have been diagnosed with AD--and that number is likely to triple by 2050. While the cause of Alzheimer s disease is still a mystery, new research has increased our knowledge of certain aspects of the disease. Perhaps most significant, studies show that proper diet may make a real difference, not only in slowing the progression of AD, but also in preventing it. In this groundbreaking book, a notable expert on Alzheimer s disease has teamed up with a leading researcher of nutrition to create a unique guide to understanding and managing this serious condition. The Alzheimer s Prevention & Treatment Diet outlines a cutting-edge nutritional program that...

On Pluto: Inside the Mind of Alzheimer's

On Pluto: Inside the Mind of Alzheimer's
by Greg O'Brien (Author), Lisa Genova (Foreword)


This is a book about living with Alzheimer’s, not dying with it. It is a book about hope, faith, and humor—a prescription far more powerful than the conventional medication available today to fight this disease.

Alzheimer’s is the sixth leading cause of death in the U.S.—and the only one of these diseases on the rise. More than 5 million Americans have been diagnosed with Alzheimer’s or a related dementia; about 35 million people worldwide.

Greg O’Brien, an award-winning investigative reporter, has been diagnosed with early-onset Alzheimer's and is one of those faceless numbers. Acting on long-term memory and skill coupled with well-developed journalistic grit, O’Brien decided to tackle the disease and his imminent decline by writing frankly about the journey....

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones
by Mary T Newport (Author)


Acting on new research showing that medium-chain fatty acids, which act like an alternative fuel in the insulin-deficient Alzheimer's brain, can sometimes reverse or at least stabilize the disease, author Dr. Mary T. Newport has demonstrated through her care for her husband that there is hope, relief, and perhaps a cure.

The 36-Hour Day: A Family Guide to Caring for People Who Have Alzheimer Disease, Related Dementias, and Memory Loss

The 36-Hour Day: A Family Guide to Caring for People Who Have Alzheimer Disease, Related Dementias, and Memory Loss
by Nancy L. Mace (Author), Peter V. Rabins (Author)


When someone in your family suffers from Alzheimer disease or other related memory loss diseases, both you and your loved one face immense challenges. For over thirty years, this book has been the trusted bible for families affected by dementia disorders. Now completely revised and updated, this guide features the latest information on the causes of dementia, managing the early stages of dementia, the prevention of dementia, and finding appropriate living arrangements for the person who has dementia when home care is no longer an option.

You'll learn:
-The basic facts about dementia
-How to deal with problems arising in daily care-- meals, exercise, personal hygiene, and safety
-How to cope with an impaired person's false ideas, suspicion, anger, and other mood...

Alzheimer 's Disease and Risks: Simplified

Alzheimer 's Disease and Risks: Simplified


This book is a comprehensive guide and review for anyone who wishes to learn about the Alzheimer’s disease. You may have someone in the family who suffers from it or you may just be curious to learn about it. Regardless, this book is sure to benefit you by providing you a complete interface of the disease. We will start from the very basics on what the disease actually is, how it starts and its scientific mechanism in comprehensive way.
In addition, the signs and symptoms will be talked about in detail in order to enable you to make an efficient diagnosis if you come across such an individual. We will also talk about who is more likely to be affected by it, how it can be treated, prevented and how to deal with it. This will be in terms of both the patient as well as the family....

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease
by Dr. Benjamin T. Mast (Author), Scotty Smith (Foreword)


Charles is 78 years old and there is much he cannot remember. He cannot remember the names of his children, why he lives in a nursing home, or even whether he ate breakfast today. His forgetting causes confusion, and in his fear and uncertainty he sometimes lashes out at those who try to care for him. But when someone reads a favorite Psalm he quickly joins in, reciting each cherished word. When he hears an old hymn of faith, his hand slowly raises and he breathes out each word quietly, his face reflecting a peace that passes all understanding. Alzheimer’s disease has been described as the “defining disease” of the baby boomer generation. Millions of Americans will spend much of their retirement years either caring for a loved one with Alzheimer’s disease or experiencing its...

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)
by Richard S Isaacson MD (Author), Christopher N Ochner PhD (Author)


Harvard-trained Neurologist, Dr. Richard Isaacson and renowned nutrition expert, Dr. Christopher Ochner team up to create this ground-breaking nutritional guide for individuals concerned about memory loss. In recent years, there has been an explosion in research on nutritional interventions for Alzheimer’s prevention and treatment, which is considered to be the most severe public health crisis of our day. These specific dietary interventions present new hope for individuals concerned about memory loss, and also have rapidly expanding scientific-evidence to support their effectiveness. Based on empirical evidence, The Alzheimer’s Diet outlines what to eat, what not to eat, and highlights a step-by-step approach for improving memory and protecting the brain through diet. This...

© 2016 BrightSurf.com